Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-01-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.